Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS.

Journal: Frontiers in pharmacology
Published Date: Dec 19, 2024

Abstract

INTRODUCTION: MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.

Authors

  • Wei Lu
    Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Rong Zeng
    Department of Health Management, Renmin Hospital of Wuhan University, Wuhan, China.
  • Meng Pan
    Department of Cardiovascular Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Yuan Zhou
    Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Huijuan Tang
    Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
  • Wanying Shen
    Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
  • Yijun Tang
    Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
  • Pan Lei
    Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals